[Experimental study of targeting therapy of breast cancer with 131I-labeled epidermal growth factor].
OBJECTIVE
To investigate the effectiveness of (131)I-epidermal growth factor (EGF) on the proliferation of a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma.


METHODS
EGF/HAS was labeled with (131)I by chloramines-T method. Human breast cancer xenografts with positive EGFR expression were established in nude mice. The nude mice were injected with normal saline, Epirubicin Hydrochloride, (131)I-EGF, (131)I-HAS, (131)I intravenously and (131)I-EGF intratumoral administration respectively. The tumor growth inhibition rate was determined by measurement of tumor volume. Different examinations were carried out.


RESULTS
There was remarkable significant difference of tumor volumes at 26th day among (131)I-EGF trial groups, (131)I, (131)I-HAS, and the negative control group. The tumor growth inhibition rate of (131)I-EGF trial groups was 82.0%, 80.7% respectively. Compared with the negative control group, the (131)I-EGF trial groups remarkably suppressed the growth of tumor (P < 0.05). Irreversible destruction of tissues in (131)I-EGF groups was observed under light and electron microscope. There was no evidence of hepatotoxicity, renal toxicity and myelotoxicity in nude mice bearing human breast cancer given (131)I-EGF over a 4-wk observation period.


CONCLUSIONS
(131)I-EGF has obvious antitumor effects on a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma, with little obvious side effects.
Xu
Wei-yun
WY
Department of Breast Surgery, Mianyang Central Hospital, Mianyang 621000, China. myxuweiyun@hotmail.com
Li
Yun-chun
YC
He
Sheng
S
Zhao
Yang-bing
YB
Li
Hong-jiang
HJ
Yao
Xian-yun
XY
D000818:Animals; D004815:Epidermal Growth Factor / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000532:radiotherapy*; D051379:Mice; D008819:Mice, Nude; D016499:Radioimmunotherapy; D023041:Xenograft Model Antitumor Assays
D007457:Iodine Radioisotopes; D004815:Epidermal Growth Factor; D066246:ErbB Receptors